Transcript Melanoma Screening and MelaFind Sam Karnes BME 281

Melanoma Screening and MelaFind
Sam Karnes
BME 281
Melanoma
• UV ray exposure damages DNA of skin cells
• Cancer cells
– Grow without control
– Invade surrounding tissues (metastasize)
• Tumors
– Cancerous vs. Benign
• Most Deadly Form of Skin Cancer but
treatable if identified early
Mela Sciences Inc
• Became a part of Electro-Optical Sciences 1989
– R&D projects for the Department of Defense
– remote sensing and image analysis
• Mid 1990s
– Worked with NYU
– Applied signal processing techniques towards medical
applications
• Developed DIFOTI, SkinSurf, SLIM, and MelaFind
MelaFind
• Provides dermatologist more information
when considering a biopsy
• Composed of
– Illuminator
• Blue to near infrared
– Lens System
– Photon Sensor
• Identifies cancerous skin lesions
– Algorithms that automatically analyze results
Results
• 1632 lesions for analysis
– 175 lesions were identified as positive
• Overall the device showed that 98.3% were melanoma
(172/175)
• Device discovered 10.8% of the negative class lesions
• Dermatologists in the study only found 5.6%.
• Avoidable biopsies reduced by 90%
Advantages
• Reduces skin cancer fatalities
• Reduces biopsy procedures
– Reduced costs
• No adverse side effects
• Approved for pre-market use in U.S. and
approved for sale in European Union
• Results are extremely accurate
Disadvantages
• Not covered by insurance
• Isopropyl alcohol used in lesion preparation
can cause skin irritation
• Not yet available to the general population
Costs
• MelaFind costs $7,500
– Includes placement and training
• Cost per patient
– $50 per lesion or ~$150 for multiple lesions
• Cost of biopsy
– Between $150 and $1000
Future of MelaFind
• Could be publically available
– Reduce size and price
– Help patients with medical history of skin cancer
• Insurance Coverage
References
•
•
•
•
•
•
•
•
•
"About MelaFind®." MELA Sciences. MELA Sciences Inc, 2012. Web.
<http://www.melasciences.com/>.
Corley, Gavin. MelaFind Device. Digital image. MelaFind Lesion Imaging Device Receives CE
Marking. N.p., n.d. Web. <http://www.medgadget.com/2011/09/melafind-lesion-imaging-devicereceives-ce-marking.html>.
Greenhalgh, Emily. +Mass Device. Massachusetts Medical Devices Journal, 3 Nov. 2011. Web.
<http://www.massdevice.com/news/mela-sciences-ceo-melafind-rollout-planned-early-2012>.
Gutkowicz-Krusin, Dina. JAMA Dermatology 147.2 (2011): 188-94. Print.
"How MelaFind Uses Military Tech To Find Cancer." Co.Exist. Ed. Morgan Clendaniel. Fast Company
and Inc, n.d. Web. <http://www.fastcoexist.com/1679933/how-melafind-uses-military-tech-to-findcancer>.
"How Much Does A Biopsy Cost?" CostEvaluation.com. N.p., n.d. Web.
<http://www.costevaluation.com/biopsy-cost.php>.
Landro, Laura. Wall Street Journal. Dow Jones and Company, 2 Sept. 2013. Web.
<http://online.wsj.com/article/SB10001424127887324009304579044850405858272.html>.
"MelaFind®." Fda.gov. FDA, 29 Sept. 2010. Web.
<http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevi
ces/MedicalDevicesAdvisoryCommittee/GeneralandPlasticSurgeryDevicesPanel/UCM233837.pdf>.
"What Is Cancer?" American Cancer Society. American Cancer Society Inc, n.d. Web.
<http://www.cancer.org/cancer/skincancer-melanoma/detailedguide/melanoma-skin-cancer-whatis-cancer>.